通用中文 | 盐酸博洛昔韦片 | 通用外文 | baloxavir marboxil |
品牌中文 | 品牌外文 | XOFLUZA | |
其他名称 | |||
公司 | 盐野义(shionogi) | 产地 | 日本(Japan) |
含量 | 20mg | 包装 | 10片/瓶 |
剂型给药 | 片剂 口服 | 储存 | 室温 |
适用范围 | 杀死A型和B型流感病毒 |
通用中文 | 盐酸博洛昔韦片 |
通用外文 | baloxavir marboxil |
品牌中文 | |
品牌外文 | XOFLUZA |
其他名称 | |
公司 | 盐野义(shionogi) |
产地 | 日本(Japan) |
含量 | 20mg |
包装 | 10片/瓶 |
剂型给药 | 片剂 口服 |
储存 | 室温 |
适用范围 | 杀死A型和B型流感病毒 |
2018年2月27日,日本卫生部已批准在一些患者中短短1天内可以杀死A型和B型流感病毒的药物baloxavir marboxil片剂。
Baloxavir marboxil是一种新型的帽子依赖性核酸内切酶抑制剂,可以在24小时内杀死流感病毒,但有些症状可能会持续更长时间。它通过与现有抗流感药物不同的机制抑制病毒复制。而流感期间被疯狂抢购的奥司他韦(达菲)起效通常要72小时。
与神经氨酸苷酶抑制剂如奥司他韦(达菲)不同, baloxavir marboxil是通过抑制病毒聚合酶的帽依赖性内切核酸酶活性来防止病毒复制。
与奥塞米韦不同,奥塞米韦需5天内每日2次服药以治疗流感,而baloxavir marboxil不论年龄大小,均可服用单次剂量,这样可以方便服用并改善依从性。
Baloxavir marboxil在被称为CAPSTONE-1的随机,双盲,多中心,平行组,安慰剂和主动对照研究中进行了测试。共纳入1436例诊断为流感的患者。
该试验的结果显示,在2017年传染病疾病周中,与安慰剂相比,baloxavir marboxil缓解症状的中位时间显着改善(80.2小时vs 53.7小时;P <0.0001)。与安慰剂相比,baloxavir marboxil缓解发热更快(42小时 vs 24.5小时,P <0 .0001)。
该研究还发现,与安慰剂或奥司他韦相比,baloxavir marboxil的关键病毒学终点显著改善。该公司报告称,在治疗开始后1,2和4天,baloxavir marboxil组确定为流感病毒滴度为阳性的患者百分比显著低于奥司他韦组。此外,与奥司他韦相比,baloxavir marboxil治疗组病毒脱落时间显著降低。
但华尔街日报称,此药物在2019年前不会在美国上市。
2018年2月27日,日本卫生部已批准在一些患者中短短1天内可以杀死A型和B型流感病毒的药物baloxavir marboxil片剂。
Baloxavir marboxil是一种新型的帽子依赖性核酸内切酶抑制剂,可以在24小时内杀死流感病毒,但有些症状可能会持续更长时间。它通过与现有抗流感药物不同的机制抑制病毒复制。而流感期间被疯狂抢购的奥司他韦(达菲)起效通常要72小时。
与神经氨酸苷酶抑制剂如奥司他韦(达菲)不同, baloxavir marboxil是通过抑制病毒聚合酶的帽依赖性内切核酸酶活性来防止病毒复制。
与奥塞米韦不同,奥塞米韦需5天内每日2次服药以治疗流感,而baloxavir marboxil不论年龄大小,均可服用单次剂量,这样可以方便服用并改善依从性。
Baloxavir marboxil在被称为CAPSTONE-1的随机,双盲,多中心,平行组,安慰剂和主动对照研究中进行了测试。共纳入1436例诊断为流感的患者。
该试验的结果显示,在2017年传染病疾病周中,与安慰剂相比,baloxavir marboxil缓解症状的中位时间显着改善(80.2小时vs 53.7小时;P <0.0001)。与安慰剂相比,baloxavir marboxil缓解发热更快(42小时 vs 24.5小时,P <0 .0001)。
该研究还发现,与安慰剂或奥司他韦相比,baloxavir marboxil的关键病毒学终点显著改善。该公司报告称,在治疗开始后1,2和4天,baloxavir marboxil组确定为流感病毒滴度为阳性的患者百分比显著低于奥司他韦组。此外,与奥司他韦相比,baloxavir marboxil治疗组病毒脱落时间显著降低。
但华尔街日报称,此药物在2019年前不会在美国上市。
Description
This medicine inhibits influenza viral growth in cells, thereby relieving symptoms of influenza.
It is usually used for the treatment of type A or type B influenza infection.
Presentation
Feature
white to light yellowish white tablet, diameter: 5.0 mm, thickness: 2.65 mm
Active Ingredients
Baloxavir marboxil 10mg
Effect/Efficacy
This medicine inhibits influenza viral growth in cells, thereby relieving symptoms of influenza.
It is usually used for the treatment of type A or type B influenza infection.
Usage/Dosage
In general, for adults and children at age of 12 years old or more, take 40 mg as active ingredient at a time, in a single dose. For these with body weight of 80 kg or more, take 80 mg at a time, in a single dose.
In general, for children at age of 12 years old or less, take 40 mg at a time for these with body weight of 40 kg or more, take 20 mg at a time for these with body weight of 20 to 40 kg, take a tablet (10 mg) at a time for these with body weight of 20 kg or less, in a single dose in each case.
Strictly follow the instructions.
If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.
Do not stop taking this medicine unless your doctor instructs you to do so.
Cautions
If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you are pregnant or breastfeeding.
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
If you are breastfeeding, avoid it while taking this medicine.
Keep the medicine out of the reach of infants and children. Store it at room temperature (1 to 30 degrees Celsius) away from direct sunlight and moisture.
Discard the remainder. Do not store them.
[To parental guardians etc.] There have been some reports on the onset of psychoneurotic symptoms such as abnormal behavior in patients treated with anti-influenza virus medicines. Therefore, you should keep the following in mind. There is a risk of occurrence of abnormal behavior in children or minors. In case of recuperation at home after the treatment with this medicine, the parental guardians etc. should make sure that the child or the minor is not left alone for at least 2 days.
Contraindication
The most commonly reported adverse reactions include diarrhea. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
No pertinent entries.
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.